Generic Opana ER® Launches

On January 7, 2013, Global Pharmaceutical received final FDA approval for and commenced shipping the generic equivalent for Endo’s branded product, Opana ER® (oxymorphone HCL) tablets. Opana ER® had estimated total U.S. annual sales of approximately $25 million.

Opana is an opioid agonist indicated for the relief of moderate to severe pain in patients requiring continuous around the clock opioid treatment for an extended period of time.